Found: 32
Select item for more details and to access through your institution.
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 894, doi. 10.1007/s10637-019-00842-z
- By:
- Publication type:
- Article
Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 874, doi. 10.1007/s10637-019-00887-0
- By:
- Publication type:
- Article
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 866, doi. 10.1007/s10637-019-00863-8
- By:
- Publication type:
- Article
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 899, doi. 10.1007/s10637-019-00846-9
- By:
- Publication type:
- Article
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 885, doi. 10.1007/s10637-020-00919-0
- By:
- Publication type:
- Article
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 831, doi. 10.1007/s10637-019-00840-1
- By:
- Publication type:
- Article
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 675, doi. 10.1007/s10637-019-00827-y
- By:
- Publication type:
- Article
Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 776, doi. 10.1007/s10637-019-00826-z
- By:
- Publication type:
- Article
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 746, doi. 10.1007/s10637-019-00831-2
- By:
- Publication type:
- Article
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 800, doi. 10.1007/s10637-019-00830-3
- By:
- Publication type:
- Article
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 812, doi. 10.1007/s10637-019-00835-y
- By:
- Publication type:
- Article
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 844, doi. 10.1007/s10637-019-00832-1
- By:
- Publication type:
- Article
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 821, doi. 10.1007/s10637-019-00824-1
- By:
- Publication type:
- Article
Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 662, doi. 10.1007/s10637-019-00823-2
- By:
- Publication type:
- Article
Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 690, doi. 10.1007/s10637-019-00816-1
- By:
- Publication type:
- Article
Targeting ROS overgeneration by N-benzyl-2-nitro-1-imidazole-acetamide as a potential therapeutic reposition approach for cancer therapy.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 785, doi. 10.1007/s10637-019-00820-5
- By:
- Publication type:
- Article
T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 722, doi. 10.1007/s10637-019-00819-y
- By:
- Publication type:
- Article
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 700, doi. 10.1007/s10637-019-00818-z
- By:
- Publication type:
- Article
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 765, doi. 10.1007/s10637-019-00815-2
- By:
- Publication type:
- Article
Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 755, doi. 10.1007/s10637-019-00821-4
- By:
- Publication type:
- Article
Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 634, doi. 10.1007/s10637-019-00813-4
- By:
- Publication type:
- Article
Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 733, doi. 10.1007/s10637-019-00812-5
- By:
- Publication type:
- Article
Vitamin K3 thio-derivative: a novel specific apoptotic inducer in the doxorubicin-sensitive and -resistant cancer cells.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 650, doi. 10.1007/s10637-019-00810-7
- By:
- Publication type:
- Article
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 599, doi. 10.1007/s10637-019-00802-7
- By:
- Publication type:
- Article
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 855, doi. 10.1007/s10637-019-00807-2
- By:
- Publication type:
- Article
The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 574, doi. 10.1007/s10637-019-00806-3
- By:
- Publication type:
- Article
Novel thiosemicarbazones induce high toxicity in estrogen-receptor-positive breast cancer cells (MCF7) and exacerbate cisplatin effectiveness in triple-negative breast (MDA-MB231) and lung adenocarcinoma (A549) cells.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 558, doi. 10.1007/s10637-019-00789-1
- By:
- Publication type:
- Article
Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 621, doi. 10.1007/s10637-019-00809-0
- By:
- Publication type:
- Article
LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 714, doi. 10.1007/s10637-019-00798-0
- By:
- Publication type:
- Article
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 610, doi. 10.1007/s10637-019-00794-4
- By:
- Publication type:
- Article
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 584, doi. 10.1007/s10637-019-00803-6
- By:
- Publication type:
- Article
Effects of chemotherapy on placental development and function using in vitro culture of human primary cytotrophoblasts.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 547, doi. 10.1007/s10637-019-00800-9
- By:
- Publication type:
- Article